DelveInsight’s “Gastric Cancer Market Insights, Epidemiology, and Market Forecast – 2034“ report provides comprehensive insights about the leading companies and therapies in the Gastric Cancer treatment landscape. It covers the Gastric Cancer drug profiles, including marketed and pipeline-stage products. It also covers the Gastric Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Gastric Cancer Treatment Landscape @ Gastric Cancer Market Outlook
Key Takeaways from the Gastric Cancer Market Report
- In February 2025 – Signet Therapeutics announced that the FDA granted Fast Track Designation to SIGX1094 for treating diffuse gastric cancer.
- In February 2025 – AstraZeneca anticipates a data readout from the Phase Ib/II DESTINY-Gastric03 trial focused on treating metastatic or unresectable HER2+ gastric, GEJ, and GEA in 2026, and expects first patient dosing of ENHERTU in the DESTINY-Gastric05 trial in Q1 2025 for HER2+ first-line locally advanced or metastatic gastric cancer.
- In January 2025 – Jazz Pharmaceuticals anticipates the potential approval and launch of zanidatamab as a first-line treatment for GEA in 2026, and presented its expanded market strategy for zanidatamab for the same year.
- In January 2025 – ALX Oncology presented positive updated data from the ASPEN-06 Phase II trial at the 2025 ASCO Gastrointestinal Cancers Symposium, demonstrating that evorpacept produces a durable clinical response and a well-tolerated safety profile in patients with previously treated HER2+ advanced gastric or GEJ cancer.
- In December 2024 – The US FDA approved TEVIMBRA, in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma in adults whose tumors express PD-L1 (≥1).
- In March 2024 – Japan’s MHLW approved VYLOY (zolbetuximab), making it the first and only CLDN18.2-targeted therapy approved by any regulatory agency in the world for patients with CLDN18.2-positive, unresectable, advanced or recurrent gastric cancer.
- DelveInsight’s Gastric Cancer market report depicts a robust space with leading companies such as AstraZeneca, Daiichi Sankyo, Bristol-Myers Squibb, Merck, Blueprint Medicines, Genentech, Astellas Pharma, BeOne Medicines (BeiGene), Jazz Pharmaceuticals, Zymeworks, ALX Oncology, Pfizer, and others.
- Promising Gastric Cancer therapies such as Bemarituzumab, ZIIHERA (zanidatamab), Rilvegostomig, AZD0901, Evorpacept, TUKYSA, A166, ELVN-002, ARX788, and others are advancing through clinical development.
Gain in-depth knowledge of key Gastric Cancer clinical trials, emerging drugs, and market opportunities @ Gastric Cancer Clinical Trials Assessment
Gastric Cancer Overview
Gastric (stomach) cancer occurs when cancer cells form in the stomach’s lining. There are 5 layers in the stomach wall — mucosa, submucosal, muscularis propria, subserosa, and serosa — and the location of the tumor and the layers involved play an important role in determining the stage of cancer, which affects treatment options and prognosis. As cancer grows from the mucosa into deeper layers, the stage becomes more advanced and demands extensive treatment.
Gastric cancer represents the fifth most prevalent malignant tumor globally, with the highest incidence rates observed in Eastern Asia and Eastern Europe. The total number of incident cases of gastric cancer (including GEJ) in the 7MM was approximately 211,550 in 2024, with Japan recording the highest at 129,500 cases. Gastric cancer is 2.2 times more likely to be diagnosed in males than females, and at the time of diagnosis, metastatic disease is present in about 35% of patients in the United States.
The total market size of HER2+ gastric cancer (including GEJ) in the 7MM is approximately USD 700 million in 2024 and is projected to increase during the forecast period (2025–2034). Several approved drugs for gastric cancer include ENHERTU, CYRAMZA, OPDIVO, KEYTRUDA, AYVAKIT, HERCEPTIN, VYLOY, and TEVIMBRA, among others.
Gastric Cancer Emerging Drugs Profile
Bemarituzumab: Amgen
Bemarituzumab is a monoclonal antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b), being investigated for the treatment of advanced gastric and gastroesophageal junction (GEJ) cancers. In April 2021, the US FDA granted Breakthrough Therapy Designation for bemarituzumab. According to Amgen’s presentations published in May 2025, the company expects to release results from the FORTITUDE-101 Phase III trial testing bemarituzumab in first-line gastric cancer in Q2 2025, with FORTITUDE-102 results expected in H2 2025. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Gastric Cancer.
ZIIHERA (Zanidatamab): Jazz Pharmaceuticals, BeiGene, and Zymeworks
ZIIHERA is a bispecific HER2-directed antibody that binds to two extracellular sites on HER2. In November 2024, the FDA granted accelerated approval to ZIIHERA for adult patients with previously treated, unresectable, or metastatic HER2+ Biliary Tract Cancer (BTC). Jazz Pharmaceuticals anticipates a top-line data readout in Q2 2025 from the pivotal Phase III HERIZON-GEA-01 trial evaluating zanidatamab in combination with chemotherapy, with or without tislelizumab, as a first-line treatment for HER2-expressing metastatic GEA. An sBLA submission for first-line GEA is anticipated in 2025. Currently, the drug is in Phase III stage of its clinical trial for Gastric Cancer.
AZD0901: AstraZeneca
AZD0901 is an antibody-drug conjugate (ADC) targeting Claudin-18.2 (CLDN18.2), being developed for second- or later-line advanced or metastatic gastric or GEJ adenocarcinoma expressing Claudin18.2. CLDN18.2 has emerged as a promising target for treating digestive malignancies due to its limited expression in healthy tissues and abnormal overexpression in various cancers. AstraZeneca anticipates data from the DESTINY-Gastric04 trial to be available in H2 2025. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Gastric Cancer.
Evorpacept (ALX148): ALX Oncology
Evorpacept is a CD47-blocking fusion protein being evaluated in second- or third-line advanced HER2-overexpressing gastric and GEJ cancer. It produces a durable clinical response by blocking the “don’t eat me” signal on cancer cells, enhancing macrophage-mediated tumor clearance. In January 2025, ALX Oncology presented positive updated data from the ASPEN-06 Phase II trial at the 2025 ASCO Gastrointestinal Cancers Symposium. Currently, the drug is in Phase II/III stage of its clinical trial for Gastric Cancer.
Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Gastric Cancer Unmet Needs
The Gastric Cancer Market Report Provides Insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Gastric Cancer with aggregate therapies developed by each company for the same.
- It assesses different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastric Cancer treatment.
- Gastric Cancer companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Gastric Cancer drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreements, and financing details for future advancement of the Gastric Cancer market.
Gastric Cancer Companies
Major Gastric Cancer Companies shaping the competitive landscape include:
- AstraZeneca,
- Daiichi Sankyo,
- Bristol-Myers Squibb,
- Merck,
- Blueprint Medicines,
- Genentech,
- Astellas Pharma,
- BeOne Medicines (BeiGene),
- Jazz Pharmaceuticals,
- Zymeworks,
- ALX Oncology,
- Pfizer, Amgen,
- Enliven Therapeutics,
- Ambrx,
- NovoCodex,
- KLUS Pharma,
- Signet Therapeutics, and others.
Gastric Cancer Market Report provides the therapeutic assessment of drugs by Route of Administration
- Intravenous
- Oral
- Subcutaneous
- Parenteral
Gastric Cancer Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Antibody-Drug Conjugate (ADC)
- Bispecific Antibody
- Small Molecule / Tyrosine Kinase Inhibitor
- Fusion Protein
See the latest progress in drug development and clinical research @ Gastric Cancer Market Drivers and Barriers, and Future Perspectives: https://www.delveinsight.com/report-store/gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Scope of the Gastric Cancer Market Report
- Coverage – Global (US, EU4 – Germany, France, Italy, Spain, United Kingdom, and Japan – 7MM)
- Gastric Cancer Companies – AstraZeneca, Daiichi Sankyo, Bristol-Myers Squibb, Merck, Blueprint Medicines, Genentech, Astellas Pharma, BeOne Medicines (BeiGene), Jazz Pharmaceuticals, Zymeworks, ALX Oncology, Pfizer, and others.
- Gastric Cancer Therapies – ENHERTU, OPDIVO, KEYTRUDA, AYVAKIT, HERCEPTIN, VYLOY, TEVIMBRA, ZIIHERA, Bemarituzumab, AZD0901, Rilvegostomig, Evorpacept, TUKYSA, and others.
- Gastric Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Gastric Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Marketed
Stay Ahead in Oncology Research – Access the Full Gastric Cancer Market Analysis Today! @ https://www.delveinsight.com/report-store/gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Table of Contents
- Introduction
- Executive Summary
- Gastric Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Gastric Cancer – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Gastric Cancer Collaboration Deals
- Marketed Products
- Late Stage Products (Phase III)
- Mid Stage Products (Phase II/III)
- Early Stage Products (Phase I)
- Preclinical Stage Products
- Inactive Products
- Gastric Cancer Key Companies
- Gastric Cancer Key Products
- Gastric Cancer – Unmet Needs
- Gastric Cancer – Market Drivers and Barriers
- Gastric Cancer – Future Perspectives and Conclusion
- Gastric Cancer Analyst Views
- Gastric Cancer Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
